Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptorpositive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial - Kogawa, T; Noguchi, E; Yamanaka, T (J Clin Oncol, 2023)